Diagnostic or prognostic study
Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
- Risk prediction model development and validation study
- pooled cohort of 4 TIMI clinical trial cohorts
- derivation and validation cohorts
Authors' conclusion
We developed and validated a risk score for atherothrombotic events, leveraging 16 routinely assessed clinical variables in patients with T2DM.
Study context
- Population
- Patients with T2DM from 4 TIMI clinical trial cohorts
- Participants
- 42,181 patients · 4 TIMI trial cohorts
- Comparison
- Top vs bottom predicted-risk quintiles
- Outcome
- MI or ischemic stroke
- Follow-up
- 3 years
Performance
As reported in the abstract
MI or IS, validation cohort · 3-year Kaplan-Meier rate
P < 0.0001
- Independent predictors of myocardial infarction (MI) or ischemic stroke (IS)
- 16
- C-index, derivation cohort
- 0.704
- C-index, validation cohort
- 0.706
Further findings
Absolute reduction in MI or IS with dapagliflozin, higher vs lower baseline predicted risk (DECLARE-TIMI 58)
- Absolute risk reduction, higher vs lower risk
- 2.1% vs 0.2%
- tended to be greater
Absolute reduction in MI or IS with evolocumab, higher vs lower baseline predicted risk (FOURIER)
- Absolute risk reduction, higher vs lower risk
- 3.2% vs 1.0%
- tended to be greater
Original publication
Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. Published 27 June 2023. doi:10.1016/j.jacc.2023.04.031
Summarised from the published abstract; every number is checked against it